文献速递妇科肿瘤

探索晚期高级别浆液性卵巢癌原发灶至复发灶中CD133/乙醛脱氢酶-1(ALDH1)阳性癌干样细胞的克隆演化:卵巢癌治疗-创新模型延长生存(OCTIPS)联盟研究

Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
PubMed 文献 · Eur J Cancer · 2017-05-16

该研究纳入112例高级别浆液性卵巢癌(HGSOC)患者的224对原发与复发配对组织,用免疫组化检测CD133和ALDH1表达。结果显示CD133染色从原发灶较高水平向复发灶较低水平显著偏移(p<0.0001),原发灶CD133/ALDH1共表达是PFI和OS的独立预后因素,且BRCA突变不影响癌干样细胞标志物表达。

要点

  • 原发灶CD133阳性患者均为FIGO III/IV期(p<0.0001),且无进展间期和总生存显著更差。
  • 原发灶CD133/ALDH1共表达是PFI(HR 1.64)和OS(HR 1.71)的独立预后因素。
  • CD133染色从原发灶较高水平向复发灶较低水平显著偏移(p<0.0001)。

核心结论

  • CD133/ALDH1表达影响HGSOC患者生存,首次提示癌干样细胞可能在病程中发生表型改变,类似非干样癌细胞,并首次提供癌干样细胞与BRCA状态无相关性的证据。

研究设计与样本

  • 研究纳入112例HGSOC患者的224对原发与复发配对组织样本,采用免疫组化评估CD133和ALDH1表达。

主要发现

  • 49.1%(55/112)的患者和37.5%(42/112)的原发灶分别为CD133+和ALDH1+;复发灶中CD133+和ALDH1+样本分别占33.9%(38/112)和36.6%(41/112)。
  • 原发灶和复发灶中CD133/ALDH1共表达分别占23.2%(26/112)和15.2%(17/112)。
  • 配对分析显示CD133染色从原发灶较高水平向复发灶较低水平显著偏移(p<0.0001)。
  • 所有CD133+原发灶患者均为FIGO III/IV期(p<0.0001),且无进展间期(p=0.04)和总生存(p=0.02)显著更差。
  • 多因素分析显示原发灶CD133/ALDH1共表达是PFI(HR 1.64;95%CI 1.03-2.60;p=0.036)和OS(HR 1.71;95%CI 1.01-2.88;p=0.045)的独立预后因素;52例已知体细胞BRCA状态的患者分析显示BRCA突变不影响癌干样细胞标志物表达。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-grade serous ovarian cancer (HGSOC) causes 80% of all ovarian cancer (OC) deaths. In this setting, the role of cancer stem-like cells (CSCs) is still unclear. In particular, the evolution of CSC biomarkers from primary (pOC) to recurrent (rOC) HGSOCs is unknown. Aim of this study was to investigate changes in CD133 and aldehyde dehydrogenase-1 (ALDH1) CSC biomarker expression in pOC and rOC HGSOCs. METHODS: Two-hundred and twenty-four pOC and rOC intrapatient paired tissue samples derived from 112 HGSOC patients were evaluated for CD133 and ALDH1 expression using immunohistochemistry (IHC); pOCs and rOCs were compared for CD133 and/or ALDH1 levels. Expression profiles were also correlated with patients' clinicopathological and survival data. RESULTS: Some 49.1% of the patient population (55/112) and 37.5% (42/112) pOCs were CD133+ and ALDH1+ respectively. CD133+ and ALDH1+ samples were detected in 33.9% (38/112) and 36.6% (41/112) rOCs. CD133/ALDH1 coexpression was observed in 23.2% (26/112) and 15.2% (17/112) of pOCs and rOCs respectively. Pairwise analysis showed a significant shift of CD133 staining from higher (pOCs) to lower expression levels (rOCs) (p < 0.0001). Furthermore, all CD133 + pOC patients were International Federation of Gynaecology and Obstetrics (FIGO)-stage III/IV (p < 0.0001) and had significantly worse progression-free interval (PFI) (p = 0.04) and overall survival (OS) (p = 0.02). On multivariate analysis, CD133/ALDH1 coexpression in pOCs was identified as independent prognostic factor for PFI (HR: 1.64; 95% CI: 1.03-2.60; p = 0.036) and OS (HR: 1.71; 95% CI: 1.01-2.88; p = 0.045). Analysis on 52 pts patients with known somatic BRCA status revealed that BRCA mutations did not influence CSC biomarker expression. CONCLUSIONS: The study showed that CD133/ALDH1 expression impacts HGSOC patients' survival and first suggests that CSCs might undergo phenotypic change during the disease course similarly to non stem-like cancer cells, providing also a first evidence that there is no correlation between CSCs and BRCA status.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ruscito I, Cacsire Castillo-Tong D, Vergote I, et al. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium. Eur J Cancer. 2017. PMID: 28525846. doi:10.1016/j.ejca.2017.04.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。